A Dose Block-randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Escalation, Phase I Clinical Trial to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Male Volunteers
Latest Information Update: 18 Jun 2020
At a glance
- Drugs Mosedipimod (Primary)
- Indications Neutropenia
- Focus Adverse reactions
- Sponsors Enzychem Lifesciences Corporation
- 26 Jan 2016 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 28 Aug 2015 New trial record